Overview

* Krystal Biotech ( KRYS ) Q2 product revenue rises to $96 mln, driven by VYJUVEK sales

* Net income for Q2 increases to $38.3 mln, reflecting strong operational performance

* VYJUVEK approved in Japan, enhancing global expansion efforts

Outlook

* Krystal Biotech ( KRYS ) expects VYJUVEK Japan launch by end of 2025

* Company plans VYJUVEK Germany launch in 3Q 2025

* Krystal Biotech ( KRYS ) sees FY 2025 non-GAAP R&D and SG&A expenses $150-$175 mln

* Company aims to report KB407 interim data by year-end

Result Drivers

* VYJUVEK SALES - $96 mln in Q2 revenue attributed to strong VYJUVEK sales

* JAPAN APPROVAL - VYJUVEK approved in Japan for DEB treatment, facilitating global expansion

* HIGH COMPLIANCE - 82% patient compliance with weekly VYJUVEK treatment reported

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $96.04

Product mln

Revenue

Q2 Net $38.33

Income mln

Q2 $56.74

Operatin mln

g

Expenses

Q2 $39.31

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Krystal Biotech Inc ( KRYS ) is $202.00, about 22.3% above its August 1 closing price of $156.98

* The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)